Evidence map›Paper›PMID 30567751›Full record

ArticleJournal of clinical microbiology2019

Public Health Efforts Can Impact Adoption of Current Susceptibility Breakpoints, but Closer Attention from Regulatory Bodies Is Needed.

James A McKinnell, S Bhaurla, P Marquez-Sung, A Pucci, M Baron, T Kamali, J Bugante, B Schwartz, S Balter, D Terashita and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Heteroresistance to piperacillin/tazobactam inJAC-antimicrobial resistance · 2024
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

James A McKinnellAcute Communicable Disease Control Unit, Los Angeles County Department of Public Health, Los Angeles, California, USA dr.mckinnell@gmail.com.
S BhaurlaAcute Communicable Disease Control Unit, Los Angeles County Department of Public Health, Los Angeles, California, USA.
P Marquez-SungAcute Communicable Disease Control Unit, Los Angeles County Department of Public Health, Los Angeles, California, USA.
A PucciAcute Communicable Disease Control Unit, Los Angeles County Department of Public Health, Los Angeles, California, USA.
M BaronAcute Communicable Disease Control Unit, Los Angeles County Department of Public Health, Los Angeles, California, USA.
T KamaliAcute Communicable Disease Control Unit, Los Angeles County Department of Public Health, Los Angeles, California, USA.
J BuganteAcute Communicable Disease Control Unit, Los Angeles County Department of Public Health, Los Angeles, California, USA.
B SchwartzAcute Communicable Disease Control Unit, Los Angeles County Department of Public Health, Los Angeles, California, USA.
S BalterAcute Communicable Disease Control Unit, Los Angeles County Department of Public Health, Los Angeles, California, USA.
D TerashitaAcute Communicable Disease Control Unit, Los Angeles County Department of Public Health, Los Angeles, California, USA.
S Butler-WuUniversity of Southern California, Los Angeles, California, USA.
J GunzenhauserAcute Communicable Disease Control Unit, Los Angeles County Department of Public Health, Los Angeles, California, USA.
J HindlerAcute Communicable Disease Control Unit, Los Angeles County Department of Public Health, Los Angeles, California, USA.
R M HumphriesDavid Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microbiological testing, including interpretation of antimicrobial susceptibility testing results using current breakpoints, is crucial for clinical care and infection control. Continued use of obsolete

Indexed as

Drug Resistance, BacterialPublic Health AdministrationAnti-Bacterial AgentsBacteriological TechniquesCarbapenemsEnterobacteriaceaeEnterobacteriaceae InfectionsHumansLos AngelesAnti-Bacterial AgentsCarbapenemsbreakpointscarbapenem resistanceCREepidemiologyKPCmicrobiologypublic healthsuperbug

Identifiers

PMID30567751
PMCPMC6425187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.